Linked Life Data

18769864

Source:http://linkedlifedata.com/resource/pubmed/id/18769864

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2009-1-21
pubmed:abstractText
We studied the effects of oral levetiracetam (LEV) (500 mg twice daily) in three women with stiff-person syndrome in a single-blind, placebo-controlled study. The severity of muscle rigidity and of paroxysmal symptoms was assessed by EMG and clinically by a rating scale of 0-4 and by the Patients Global Impressions Scale. LEV was well tolerated. On active treatment all patients improved as assessed by any of the objective or subjective outcome measures. No response was noticed on placebo. Our data indicate that in patients with SPS, LEV is well tolerated and has a therapeutic role in the management of both muscle stiffness and life-threatening paroxysmal respiratory spasms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0340-5354
pubmed:author
pubmed:issnType
Print
pubmed:volume
255
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1721-5
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Levetiracetam in stiff-person syndrome.
pubmed:affiliation
Dept. of Neurosciences, University of Sassari, viale S. Pietro, 10, 07100 Sassari, Italy. gpsechi@uniss.it
pubmed:publicationType
Journal Article, Case Reports, Controlled Clinical Trial